Bristol-Myers Squibb (NYSE: BMY) Profits Underestimated, and Company Has Room for Further Growth

0

The market of Bristol-Myers Squibb Company Stocks (NYSE: BMY) haven’t moved much after posting weak earnings recently, but currently appear to be in a bearish race. In the face of uncertainty, it is always good to go back to the fundamentals and see the performance and future growth capabilities of the business.

We have dug a bit, and we believe the earnings are stronger than they appear, and there is room for growth in new products to market.

In this article, we will analyze both the growth prospects and the fundamental performance of the company.

Growth drivers

Bristol-Myers Squibb recently strengthened its product portfolio with new additions, and we are just starting to see revenue from these products in an early stage.

These new products are the engine that will keep the turnover growth rate at a sustainable level. Analysts who follow the company estimate an annual revenue growth rate of 3%.

NYSE: BMY Revenue and Revenue History September 14, 2021

From the chart above, we can see that the company has 4 items down, 3 items that have gained over 10% in the last six months, and perhaps the most important – it has 6 new items. with an uncertain future. It is in the latter group that the potential for value resides, as the investors who make the most accurate estimate of the growth of new products are those who are most likely to benefit.

Overall, it looks like the company will continue with weak but steady growth, which investors might look forward to, especially given recent volatility.

Fundamental performance

There are a few key aspects to fundamental business performance. First, the successful revenue growth since 2020, which gives the business a lot more leeway, especially as revenue moves efficiently relative to costs.

Over the past twelve months – ending June 30, we are seeing 27% revenue growth and only 1% growth in COGS (cost of goods sold) – This scaling will increase margins and drive more cash flow for Bristol-Myers Squibb.

Another aspect is negative net income, which deviates from the company’s free cash flow. We will analyze both further below.

Check out our latest review for Bristol-Myers Squibb

income-and-income-history
NYSE: BMY Revenue and Revenue History September 14, 2021

Review of Bristol-Myers Squibb Cash Flow vs. Profits

A key financial ratio used to measure how well a business converts earnings into free cash flow (FCF) is the accumulation rate. Simply put, this ratio subtracts FCF from net income and divides that number by the company’s average operating assets over that period.

The ratio shows us by how much a company’s profit exceeds its FCF.

Therefore, it is actually considered a good thing when a company has a negative accumulation ratio, but a bad thing if its accumulation ratio is positive.

For the year up to June 2021, Bristol-Myers Squibb had a accumulation ratio of -0.24.

This implies that he has a very good cash conversion and that his income from last year significantly underestimates his free cash flow.

The company generated free cash flow of US $ 12 billion during the period, eclipsing its reported profit of – US $ 5.08 billion.

However, that’s not all there is to consider. We note that unusual elements have impacted its statutory result, and therefore the accrual ratio.

How do unusual items influence profit?

Bristol-Myers Squibb profit was reduced by unusual items worth US $ 13 billion over the past twelve months which helped it generate a high cash conversion as evidenced by its items unusual. This is what you would expect to see when a business has non-cash fees that reduce paper profits.

In the twelve months leading up to June 2021, Bristol-Myers Squibb had a large expenditure of unusual items. All other things being equal, this would likely have the effect of making the statutory profit appear worse than its underlying profit power.

Conclusion

The company offers a renewed product portfolio that has the potential to generate further future growth. The new drugs are at a relatively new stage in the sales cycle, but that also means they have a long patent life ahead of them.

Fundamental performance is stabilizing and revenues are moving much better than costs. This paves the way for higher EBIT margins in the future.

Considering both Bristol-Myers Squibb’s build-up ratio and its unusual elements, we believe its statutory earnings are unlikely to overstate the underlying earnings power of the company. Based on these factors, we believe that Bristol-Myers Squibb’s underlying profit potential is as good, if not possibly better, than the statutory profit suggests!

So while the quality of the benefits is important, it is just as important to consider the risks that Bristol-Myers Squibb currently faces. During our analysis, we found that Bristol-Myers Squibb has 3 warning signs and it would be unwise to ignore them.

Simply Wall St analyst Goran Damchevski and Simply Wall St have no positions in any of the companies mentioned. This article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents.

Do you have any feedback on this item? Are you worried about the content? Contact us directly. You can also send an email to [email protected]

Share.

About Author

Leave A Reply